Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02448368 · ClinicalTrials.gov registry record · Phase 1
RDEA3170 Tablet and Capsule Bioavailability Study
A Phase 1 study, sponsored by Ardea Biosciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
NCT02448368 is a Phase 1 study that has completed, run by Ardea Biosciences. The registered enrollment target is 35 participants.
The verdict
NCT02448368, a Phase 1 study, has completed, sponsored by Ardea Biosciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the relative bioavailability of RDEA3170 capsules compared with RDEA3170 tablets.
Interventions
- DRUG RDEA3170,10 mg
- DRUG RDEA3170, 2.5 mg
- DRUG RDEA3170, 5 mg
- DRUG RDEA3170, 10 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2015-05-01 |
| Est. Completion | 2016-01-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02448368
The ClinicalTrials.gov registry entry for NCT02448368 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ardea Biosciences, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which RDEA3170,10 mg is the first listed.
NCT02448368 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02448368 about?
NCT02448368 is a clinical study titled "RDEA3170 Tablet and Capsule Bioavailability Study". The purpose of this study is to determine the relative bioavailability of RDEA3170 capsules compared with RDEA3170 tablets.
What is the current status of trial NCT02448368?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2015-05-01. Estimated completion is 2016-01-29.
What interventions are being tested in trial NCT02448368?
The interventions under investigation include: RDEA3170,10 mg (DRUG), RDEA3170, 2.5 mg (DRUG), RDEA3170, 5 mg (DRUG), RDEA3170, 10 mg (DRUG).
Who is sponsoring clinical trial NCT02448368?
This trial is sponsored by Ardea Biosciences, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.